KOVANAZE (Oxymetazoline Hydrochloride; Tetracaine Hydrochloride) Patent Expiration, LOE Window & CMS Spending

KOVANAZE (Oxymetazoline Hydrochloride; Tetracaine Hydrochloride) by St Renatus: FDA Orange Book core substance LOE 2030-04-02, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSt Renatus
FDA Application & PathwayN208032 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2030-04-02
Last Listed Patent or Exclusivity Date2030-04-02
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel